ENDOCRINE EFFECTS OF SPIRONOLACTONE IN MAN
- 1 November 1978
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 9 (5) , 389-399
- https://doi.org/10.1111/j.1365-2265.1978.tb03578.x
Abstract
SUMMARY: A double blind, controlled study was carried out in order to investigate the effects of administering spironolactone, 200 mg daily, to five healthy male volunteers. The patterns of change in plasma testosterone (T) and luteinizing hormone (LH) after spironolactone were significantly different from placebo and there were significant increases in the urinary excretion of androsterone (A), aetiocholanolone (EC) and total oestrogen. Urinary dehydroepiandrosterone (DHA) excretion, after an initial rise, declined progressively during the treatment period relative to controls. The results are discussed in the light of previous observations. It is concluded that treatment with spironolactone for 2–4 days will lead to a transient rise in plasma T and urinary DHA. Continued treatment (4–10 days) is thought to cause increased LH secretion, with normalization of plasma T and DHA excretion. These changes are accompanied by increased androgen catabolism and a slightly increased conversion of androgens to oestrogens. Healthy men may therefore show alterations in sex steroid metabolism if treated for several days with high doses of spironolactone.This publication has 40 references indexed in Scilit:
- Possibility of Adrenal-Testicular Interaction as Indicated by Plasma Androgens in Response to HCG in Men with Normal, Suppressed and Impaired Adrenal FunctionHormone and Metabolic Research, 1975
- THE MEASUREMENT OF TESTOSTERONE IN PLASMAClinical Endocrinology, 1974
- 319. Spironolactone interference with androgen production in hirsute femalesJournal of Steroid Biochemistry, 1974
- Gynecomastia and impotence: complications of spironolactone therapyPublished by American Medical Association (AMA) ,1973
- Antiandrogens. 2',3'.alpha.-Tetrahydrofuran-2'-spiro-17-(1,2.alpha.-methylene-4-androsten-3-ones)Journal of Medicinal Chemistry, 1972
- A double-blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophyBritish Journal of Surgery, 1971
- The Effect of Anti-Androgens on the Response of Rat Preputial Glands to Testosterone*Journal of Investigative Dermatology, 1964
- SPIRONOLACTONE AND GYNqCOMASTIAThe Lancet, 1963
- SPIRONOLACTONE AND GYNÆCOMASTIAThe Lancet, 1962
- SPIRONOLACTONE AND GYNÆCOMASTIAThe Lancet, 1962